Veru Inc. has entered into a clinical supply agreement with Novo Nordisk A/S to support its Phase 2b PLATEAU clinical study. The study will evaluate the combination of Veru's enobosarm with Novo Nordisk's popular weight-loss drug, Wegovy® (semaglutide), in older adults with obesity.
Key Details
- Agreement: On June 2, 2026, Veru secured an agreement where Novo Nordisk will supply Wegovy® at no charge for the duration of the Phase 2b PLATEAU study.
- Study Focus: The trial aims to assess the efficacy of combining enobosarm with Wegovy® therapy for weight reduction, potentially preserving lean muscle mass.
- Commercial Terms: Veru retains full global development and commercialization rights to enobosarm but has granted Novo Nordisk a right of first negotiation if Veru decides to partner or commercialize enobosarm in combination with a Novo Nordisk GLP-1 product.